CL2019000124A1 - Anticuerpos anti-virus del zika y métodos de uso. - Google Patents
Anticuerpos anti-virus del zika y métodos de uso.Info
- Publication number
- CL2019000124A1 CL2019000124A1 CL2019000124A CL2019000124A CL2019000124A1 CL 2019000124 A1 CL2019000124 A1 CL 2019000124A1 CL 2019000124 A CL2019000124 A CL 2019000124A CL 2019000124 A CL2019000124 A CL 2019000124A CL 2019000124 A1 CL2019000124 A1 CL 2019000124A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- zikv
- methods
- zika virus
- virus antibodies
- Prior art date
Links
- 241000907316 Zika virus Species 0.000 title abstract 4
- 208000001455 Zika Virus Infection Diseases 0.000 abstract 1
- 208000020329 Zika virus infectious disease Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA ANTICUERPOS MONOCLONALES O FRAGMENTOS DE UNIÓN AL ANTÍGENO DE ESTOS, QUE SE UNEN A GLICOPROTEÍNAS DEL ZIKV, COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS ANTICUERPOS Y MÉTODOS DE USO. LOS ANTICUERPOS DE LA INVENCIÓN SON ÚTILES PARA INHIBIR O NEUTRALIZAR LA ACTIVIDAD DEL ZIKV, CON LO CUAL SE BRINDA UN MEDIO PARA TRATAR O PREVENIR LA INFECCIÓN POR ZIKV EN HUMANOS. EN ALGUNAS MODALIDADES, LA INVENCIÓN PROPORCIONA EL USO DE UNO O MÁS ANTICUERPOS QUE SE UNEN AL ZIKV PARA PREVENIR LA UNIÓN VIRAL Y/O EL INGRESO EN CÉLULAS HOSPEDADORAS. LOS ANTICUERPOS DE LA INVENCIÓN SE PUEDEN UTILIZAR DE FORMA PROFILÁCTICA O TERAPÉUTICA Y SE PUEDEN UTILIZAR SOLOS O EN COMBINACIÓN CON UNO O MÁS AGENTES ANTIVIRALES O VACUNAS ADICIONALES.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363546P | 2016-07-18 | 2016-07-18 | |
| US201762474753P | 2017-03-22 | 2017-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000124A1 true CL2019000124A1 (es) | 2019-04-05 |
Family
ID=59416830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000124A CL2019000124A1 (es) | 2016-07-18 | 2019-01-16 | Anticuerpos anti-virus del zika y métodos de uso. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10421804B2 (es) |
| EP (1) | EP3484917A1 (es) |
| JP (1) | JP6993401B2 (es) |
| KR (1) | KR20190030206A (es) |
| CN (1) | CN109641952A (es) |
| AU (1) | AU2017300277A1 (es) |
| BR (1) | BR112019000798A2 (es) |
| CA (1) | CA3030618A1 (es) |
| CL (1) | CL2019000124A1 (es) |
| CO (1) | CO2019000968A2 (es) |
| IL (1) | IL263818A (es) |
| MA (1) | MA45671A (es) |
| MX (1) | MX2019000761A (es) |
| PH (1) | PH12018502673A1 (es) |
| SG (1) | SG11201811363YA (es) |
| TW (1) | TW201815821A (es) |
| UY (1) | UY37336A (es) |
| WO (1) | WO2018017497A1 (es) |
| ZA (1) | ZA201808603B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018010789A1 (en) | 2016-07-13 | 2018-01-18 | Humabs Biomed Sa | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| BR112020002050A2 (pt) * | 2017-08-03 | 2020-09-08 | Antheia, Inc. | epimerases engenheiradas alcaloides benzilisoquinolina e métodos de produção de alcaloides benzilisoquinolina |
| WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
| JP2021518343A (ja) * | 2018-03-15 | 2021-08-02 | 中外製薬株式会社 | ジカウイルスに対して交差反応性を有する抗デングウイルス抗体および使用方法 |
| US11254953B2 (en) | 2018-04-18 | 2022-02-22 | Utah State University | Compositions and methods for zika virus characterization and vaccine development |
| US11884718B2 (en) | 2018-04-24 | 2024-01-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination |
| AU2019331024A1 (en) | 2018-08-31 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies |
| WO2020061159A1 (en) * | 2018-09-20 | 2020-03-26 | Vanderbilt University | Human antibodies to zika virus |
| JP7463366B2 (ja) | 2018-11-20 | 2024-04-08 | タケダ ワクチン，インコーポレイテッド | 新規の抗ジカウイルス抗体及びその使用 |
| AU2020256225A1 (en) * | 2019-04-03 | 2021-09-02 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for insertion of antibody coding sequences into a safe harbor locus |
| CN111138534B (zh) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | 寨卡病毒囊膜蛋白的鼠源单克隆抗体 |
| CN111100201B (zh) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | 针对寨卡病毒囊膜蛋白的鼠源单克隆抗体 |
| US20230204567A1 (en) | 2020-05-20 | 2023-06-29 | Takeda Vaccines, Inc. | Method for determining the potency of antigens |
| US20230324404A1 (en) | 2020-05-20 | 2023-10-12 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| WO2021236225A1 (en) | 2020-05-20 | 2021-11-25 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| CN115697392A (zh) * | 2020-06-28 | 2023-02-03 | 神州细胞工程有限公司 | 一种降低病毒ade效应的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| TW200838550A (en) | 2007-02-09 | 2008-10-01 | Novartis Ag | Organic compounds |
| CN103833855A (zh) | 2009-06-26 | 2014-06-04 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
| MX366103B (es) | 2012-09-12 | 2019-06-27 | Genzyme Corp | Polipeptidos que contienen fc con glicosilacion alterada y funcion efectora reducida. |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| JO3701B1 (ar) * | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
-
2017
- 2017-07-14 TW TW106123586A patent/TW201815821A/zh unknown
- 2017-07-17 EP EP17745595.3A patent/EP3484917A1/en active Pending
- 2017-07-17 CA CA3030618A patent/CA3030618A1/en not_active Abandoned
- 2017-07-17 JP JP2019502258A patent/JP6993401B2/ja active Active
- 2017-07-17 WO PCT/US2017/042447 patent/WO2018017497A1/en unknown
- 2017-07-17 MX MX2019000761A patent/MX2019000761A/es unknown
- 2017-07-17 AU AU2017300277A patent/AU2017300277A1/en not_active Abandoned
- 2017-07-17 KR KR1020197000620A patent/KR20190030206A/ko unknown
- 2017-07-17 SG SG11201811363YA patent/SG11201811363YA/en unknown
- 2017-07-17 CN CN201780041806.7A patent/CN109641952A/zh active Pending
- 2017-07-17 MA MA045671A patent/MA45671A/fr unknown
- 2017-07-17 US US15/651,387 patent/US10421804B2/en active Active
- 2017-07-17 BR BR112019000798A patent/BR112019000798A2/pt not_active IP Right Cessation
- 2017-07-19 UY UY0001037336A patent/UY37336A/es not_active Application Discontinuation
-
2018
- 2018-12-18 PH PH12018502673A patent/PH12018502673A1/en unknown
- 2018-12-19 IL IL263818A patent/IL263818A/en unknown
- 2018-12-20 ZA ZA2018/08603A patent/ZA201808603B/en unknown
-
2019
- 2019-01-16 CL CL2019000124A patent/CL2019000124A1/es unknown
- 2019-01-31 CO CONC2019/0000968A patent/CO2019000968A2/es unknown
- 2019-08-09 US US16/536,531 patent/US11117955B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MA45671A (fr) | 2021-04-07 |
| ZA201808603B (en) | 2019-08-28 |
| US10421804B2 (en) | 2019-09-24 |
| WO2018017497A1 (en) | 2018-01-25 |
| EP3484917A1 (en) | 2019-05-22 |
| US11117955B2 (en) | 2021-09-14 |
| IL263818A (en) | 2019-01-31 |
| CN109641952A (zh) | 2019-04-16 |
| SG11201811363YA (en) | 2019-01-30 |
| JP2019528050A (ja) | 2019-10-10 |
| UY37336A (es) | 2018-02-28 |
| MX2019000761A (es) | 2019-07-04 |
| CA3030618A1 (en) | 2018-01-25 |
| KR20190030206A (ko) | 2019-03-21 |
| CO2019000968A2 (es) | 2019-04-30 |
| US20200062831A1 (en) | 2020-02-27 |
| US20180016324A1 (en) | 2018-01-18 |
| PH12018502673A1 (en) | 2019-11-11 |
| AU2017300277A1 (en) | 2019-02-07 |
| TW201815821A (zh) | 2018-05-01 |
| JP6993401B2 (ja) | 2022-02-04 |
| BR112019000798A2 (pt) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019000124A1 (es) | Anticuerpos anti-virus del zika y métodos de uso. | |
| CL2020000498A1 (es) | Composiciones farmacéuticas que contienen anticuerpos contra la glicoproteína del virus ébola. (divisional solicitud 201701920) | |
| CL2018000744A1 (es) | Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso. | |
| CL2019000277A1 (es) | Tratamiento conjunto contra el cáncer. | |
| CL2017000335A1 (es) | Tratamientos conjuntos con anticuerpos anti cd40 | |
| CL2019000760A1 (es) | Tratamiento de migraña refractaria | |
| CL2017000250A1 (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
| CL2016003346A1 (es) | Anticuerpos anti-tau humanizados | |
| DOP2015000227A (es) | Virus de la enfermedad de newcastle y usos de los mismos | |
| CL2017001610A1 (es) | Anticuerpos humanos para hemagglutinina de influenza | |
| CU24533B1 (es) | Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| CL2017002596A1 (es) | Neutralización del virus chikungunya mediada por anticuerpos | |
| EA201890454A1 (ru) | Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств | |
| BR112018073238A2 (pt) | vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer | |
| CO2020013833A2 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
| CL2021000258A1 (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
| CL2018002793A1 (es) | Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control | |
| EA201792058A1 (ru) | Виротерапия комбинацией антител | |
| EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
| BR112016015078A2 (pt) | método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica | |
| EA201690383A1 (ru) | НОВЫЕ АНТИТЕЛА К FC-γ-РЕЦЕПТОРУ IIB И ИХ ПРИМЕНЕНИЯ | |
| PE20171734A1 (es) | Anticuerpos monoclonales especificos del antigeno m del virus metapneumovirus humano (hmpv) y su uso en un metodo de diagnostico | |
| CL2018001873A1 (es) | Anticuerpos igy para la prevención de infestación e infección de liendres marinas |